Loading
A phase 1 trial of 225Ac/64Cu-PD-32766 (CA9 theranostic pair) run by PeptiDream Inc., now recruiting.
A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma is a phase 1 interventional study registered as NCT07688187 by PeptiDream Inc., with 60 participants planned, started 2026-07-07. Conditions recorded: Clear Cell Renal Cell Carcinoma. Interventions recorded: PD-32766D (a Copper-64 [64Cu] labeled peptide) and PD-32766T (an Actinium-225 [225Ac] labeled peptide).
Shares PeptiDream and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Shares Clear cell renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/